0RQJ Stock Overview
Saniona AB (publ), a biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Denmark.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Saniona AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr1.87 |
| 52 Week High | kr12.38 |
| 52 Week Low | kr1.78 |
| Beta | 1 |
| 1 Month Change | -1.99% |
| 3 Month Change | -27.88% |
| 1 Year Change | -77.05% |
| 3 Year Change | -92.53% |
| 5 Year Change | -92.85% |
| Change since IPO | -96.12% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0RQJ | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 1.0% | -2.4% | -1.4% |
| 1Y | -77.1% | -29.6% | -2.4% |
Return vs Industry: 0RQJ underperformed the UK Biotechs industry which returned -29.6% over the past year.
Return vs Market: 0RQJ underperformed the UK Market which returned -2.4% over the past year.
Price Volatility
| 0RQJ volatility | |
|---|---|
| 0RQJ Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.5% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0RQJ's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 0RQJ's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 23 | Thomas Feldthus | www.saniona.com |
Saniona AB (publ), a biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Denmark. It also develops medicines modulating ion channels. The company’s products include Tesofensine, a monoamine reuptake inhibitor; and Tesomet, a fixed dose combination of tesofensine and metoprolol that has completed the Phase 2 clinical trials for the treatment of prader-willi syndrome and hypothalamic obesity.
Saniona AB (publ) Fundamentals Summary
| 0RQJ fundamental statistics | |
|---|---|
| Market cap | kr209.80m |
| Earnings (TTM) | -kr95.81m |
| Revenue (TTM) | kr16.84m |
12.5x
P/S Ratio-2.2x
P/E RatioIs 0RQJ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0RQJ income statement (TTM) | |
|---|---|
| Revenue | kr16.84m |
| Cost of Revenue | kr5.06m |
| Gross Profit | kr11.78m |
| Other Expenses | kr107.59m |
| Earnings | -kr95.81m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | -0.86 |
| Gross Margin | 69.96% |
| Net Profit Margin | -568.94% |
| Debt/Equity Ratio | -297.3% |
How did 0RQJ perform over the long term?
See historical performance and comparison